Smac mimetics are a very promising new class of anticancer agents demonstrating an acceptable safety profile and efficacy in some preclinical models of cancers when used as a single agent or in combination with conventional or nonconventional therapies. Future preclinical and clinical trials could enlarge their spectral of action in inflammatory, fibrotic and infectious diseases.
No takes yet. Share an insight, caveat, or question.
Laurence Dubrez (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: